STOCK TITAN

Prothena to Participate in 2023 Bank of America Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Prothena Corporation plc (NASDAQ:PRTA), a clinical biotechnology firm, announced its participation in a fireside chat at the 2023 Bank of America Healthcare Conference in Las Vegas on May 9, 2023, at 9:20 AM PT. This event will showcase insights from the company’s senior management regarding their investigational therapeutics pipeline, focusing on protein dysregulation and neurodegenerative diseases. A live webcast of the chat will be available on Prothena's investor relations website, with a replay accessible for 90 days afterward. Prothena specializes in developing treatments for conditions like AL amyloidosis, ATTR amyloidosis, Alzheimer’s, and Parkinson’s diseases, positioning itself as a key player in addressing these pressing health challenges.

Positive
  • None.
Negative
  • None.

DUBLIN--(BUSINESS WIRE)-- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the 2023 Bank of America Healthcare Conference in Las Vegas on Tuesday, May 9, 2023 at 9:20 AM PT.

A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Investors

IR@prothena.com

Media

Michael Bachner, Senior Director, Corporate Communications

609-664-7308, michael.bachner@prothena.com

Source: Prothena Corporation plc

FAQ

When will Prothena participate in the Bank of America Healthcare Conference?

Prothena will participate in the Bank of America Healthcare Conference on May 9, 2023, at 9:20 AM PT.

How can I watch the Prothena fireside chat?

The Prothena fireside chat can be accessed live through the investor relations section of their website, and a replay will be available for 90 days after the event.

What is Prothena Corporation's focus in biotechnology?

Prothena Corporation focuses on investigational therapeutics targeting protein dysregulation, particularly in neurodegenerative diseases and amyloid conditions.

What diseases is Prothena developing treatments for?

Prothena is developing treatments for AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative diseases.

Where is the Bank of America Healthcare Conference being held?

The Bank of America Healthcare Conference is being held in Las Vegas.

Prothena Corporation plc Ordinary Shares

NASDAQ:PRTA

PRTA Rankings

PRTA Latest News

PRTA Stock Data

643.01M
46.57M
13.46%
96.98%
14.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DUBLIN 2